CASI Pharmaceuticals, Inc.
|
|
- Solomon Paul
- 5 years ago
- Views:
Transcription
1 CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI
2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forwardlooking statements speak only as of the date they are made, and no duty to update forwardlooking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission ("SEC"), which are available at Slide 2
3 Who We Are CASI Pharmaceuticals, Inc. is a US-headquartered, NASDAQ-listed biopharmaceutical company with a dedicated regional focus and strong presence in China Focused on the acquisition, development, and commercialization of oncology assets for China and other global markets Core competency is to conduct high quality global clinical trials in China for drug candidates from Western countries with efficiency and speed under international standards Management team has practical drug development experience both in the US and China, with proven track record of successful Chinese FDA filings and approvals Financially strong with backing from IDG-Accel and Kleiner Perkins Caufield & Byers as our shareholders Our unique US/China approach positions us to help our partners strategically advance their clinical assets cost-effectively Slide 3
4 What We Can Do For You Launch your product in China up to three years sooner than a more traditional development approach Have your global Phase 3 programs completed faster Accelerate your Phase 1 and 2 clinical candidates and reach proof-ofconcept inflection points or expand into additional indications Clinical data generated in China can be utilized for your global development and regulatory filings in the US We will cover development costs in China In return we seek exclusive rights in China through in-licensing/codevelopment arrangements Slide 4
5 Why China? China s pharmaceutical spending is expected to grow 14-17% per annum over the next 5 years, reaching $170 billion and becoming the 2 nd largest market in the world by Now is the time to gain a foothold in the Chinese market. Slide 5
6 Why China Oncology? China s oncology market is growing at a rapid rate due to an increase in cancer incidence. It will likely become the world s largest market in the next 5-10 years. Slide 6
7 A Seasoned, Bi-Cultural Board and Senior Management Team BOARD OF DIRECTORS Dr. Wei-Wu He, Chairman CEO and Chairman of OriGene Technologies, Inc.; healthcare venture partner of IDG-Accel, a major venture capital firm in Asia; founder and General Partner of Emerging Technology Partners, LLC, a life sciences focused venture fund. Dr. He is a seasoned leader in the biotechnology industry with solid financing and business acumen in the U.S. and China. Dr. Tak W. Mak, Chief Scientific Advisor Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a University Professor at University of Toronto; Former VP Research at Amgen; Best known as leading scientist to first clone the genes of the human T cell antigen receptor. Dr. Mak s current and past groundbreaking research has earned him numerous awards. James Huang Managing partner of Kleiner Perkins Caufield & Byers China, with 20+ years experience in the biopharmaceutical industry, including financing and business development. Mr. Huang has deep experience, numerous contacts and extensive industry knowledge in the U.S. and China. OFFICERS Dr. Ken K. Ren, CEO Formerly an entrepreneur and seasoned executive with healthcare companies, including serving as the President of Accelovance (China) where Dr. Ren oversaw multiple global clinical trials including regulatory and development activities in China for international companies such as J&J, Eli Lilly, Novartis and Amgen. Dr. Ren started his career as a research scientist, and holds a MD from the Shandong University School of Medicine and a PhD from the State University of New York at Buffalo. Cynthia W. Hu, COO, General Counsel & Secretary Experienced biotech executive in corporate development, financing, legal and operations. Ms. Hu started her career as a corporate attorney specializing in corporate finance, securities, M&A, and public company governance. Sara Capitelli, VP Finance, Principal Accounting Officer Experienced in public company accounting and finance. Former experience includes serving as senior manager at Ernst & Young providing accounting and audit services to clients in a variety of industries. Dr. Y. Alexander Wu CEO and co-founder, Crown Biosciences, Inc., with 20+ years experience in the biopharmaceutical industry in the oncology sector, and has held senior positions in research, business development, and corporate strategy. Dr. Wu manages his business in the U.S. and China and has extensive industry knowledge in both countries. Franklin C. Salisbury, Jr., M.Div., J.D. President of the National Foundation for Cancer Research (NFCR) since 1997, leading NFCR to expand its cancer research program from basic cancer research to translational and clinical research. Mr. Salisbury also serves on the Board for the Asian Fund for Cancer Research based in Hong Kong, China, NFCR s sister foundation. Slide 7
NASDAQ: CASI Partnering Presentation
NASDAQ: CASI Partnering Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to
More informationNASDAQ: CASI. June 2018
NASDAQ: CASI June 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for
More informationGenerex Announces Appointment of Executive Management Team
Generex Announces Appointment of Executive Management Team Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth MIRAMAR, FL, November 15, 2018 -- Generex Biotechnology Corporation
More informationSeptember 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board
AGENDA SPECIAL CALLED TELEPHONE MEETING of THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS September 18, 2017 Austin, Texas Page CONVENE THE BOARD IN OPEN SESSION TO RECESS TO EXECUTIVE SESSION PURSUANT
More informationGlobal Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner
Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K. ALCON INC. (Registrant Name)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2019
More informationExperiences of an aspiring young scientist-entrepreneur
Experiences of an aspiring young scientist-entrepreneur Francis W. Hunter Auckland Cancer Society Research Centre Spark Entrepreneurship Challenge Mesopharm Therapeutics, Inc. 5 May 2014 Background Auckland
More informationALANCO TECHNOLOGIES INC
SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution
More informationFINC915 Venture Lab Participating Firms: FALL 2009
FINC915 Venture Lab Participating Firms: FALL 2009 and allowing the fund members to capitalize on high-growth opportunities. LOCAL FIRMS: MK Capital Task description: various Location: Northbrook, IL Fund
More informationMara H. Rogers, Partner Norton Rose Fulbright
Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers
More informationPRINCIPAL FINANCIAL GROUP, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationFinal Pitch Competition PROGRAM GUIDE. Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV
Final Pitch Competition PROGRAM GUIDE Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV #HITVenture #HIMSS16 1 Presented by: WEDNESDAY, MARCH
More informationQI Comes of Age: Health Reform Accelerates
12 th Annual ATP Alumni Conference QI Comes of Age: Health Reform Accelerates February 15-17, 2017 At Newpark Resort in Park City, Utah 2009 ATP Alumni Conference. February 10-12, 2010, Newpark Resort,
More informationBiotech Concerto #6 Investment Process December 2008
Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSESSION 4: Mr. Hanson Cheah, Managing Partner, AsiaTech Ventures Limited, Hong Kong
OECD/ADBI 7 th Round Table on Capital Market Reform in Asia 27-28 October 2005, Tokyo SESSION 4: Mr. Hanson Cheah, Managing Partner, AsiaTech Ventures Limited, Hong Kong Venture Capital in Asia Before
More informationCareer Forum Profile. Mr. Clement Chan Managing Director, BDO Limited & President, Hong Kong Institute of CPAs
Mr. Clement Chan is the President of the Hong Kong Institute of Certified Public Accountants. He has actively participated in standards setting and governance activities both in Hong Kong and at international
More informationOmeros Raises More Than $63 Million in Financing
Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,
More informationANNUAL GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES
ANNUAL GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES The following items on the agenda of the meeting shall be discussed and/or put to a vote. The numbers in the list correspond to the numbers on the
More informationAstellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting Tokyo, Japan March 16, 2010 Astellas Pharma Inc. (TSE: 4503) today notified
More informationLIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCLIFFS NATURAL RESOURCES INC.
CLIFFS NATURAL RESOURCES INC. FORM 8-K (Current report filing) Filed 10/17/07 for the Period Ending 10/15/07 Address 200 PUBLIC SQUARE STE. 3300 CLEVELAND, OH 44114-2315 Telephone 216-694-5700 CIK 0000764065
More informationCross-Border R&D in China Understanding the Regulatory Challenges
1 2 Cross-Border R&D in China Understanding the Regulatory Challenges 1 Panelists Moderator: Paul A. Stewart, Silicon Valley Office Managing Partner, Foley & Lardner LLP Speakers: David Rosen, Partner,
More informationPurvi B. Maniar Member of the Firm
Purvi B. Maniar Member of the Firm New York 250 Park Avenue New York, New York 10177 Tel: 212-351-3757 Fax: 212-878-8600 St. Louis Tel: 314-395-2775 pmaniar@ebglaw.com PURVI B. MANIAR is a Member of the
More informationInvestor Presentation. May 2016
Investor Presentation May 2016 Disclaimer This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward
More informationBrevitas, located in San Francisco, is a real estate collaboration and workflow platform.
PRESS KIT Our Story Brevitas, located in San Francisco, is a real estate collaboration and workflow platform. We originally served as a software solution for private real estate transactions. In 2016,
More informationPwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update
PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease
More informationIgor Fisch. New candidate, independent
Igor Fisch New candidate, independent Igor Fisch is a co-founder of Selexis SA, a biotech company based in Switzerland. He grew the company from inception to profits in less than 5 years with up to > 5MCHF
More informationKELSO TECHNOLOGIES INC.
CC BY-SA KELSO TECHNOLOGIES INC. CORPORATE PRESENTATION DISCLAIMER Legal Notice Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of applicable
More informationLISA TILTON-McCARTHY
LISA TILTON-McCARTHY Lisa Tilton-McCarthy received a B.A. in English from Texas A&M University in College Station and graduated summa cum laude from South Texas College of Law in Houston. She was Editor-in-Chief
More informationCronos Capital
Cronos Capital overview Overview Cronos Group, formerly known as PharmaCan Capital Corp., is a vertically integrated cannabis company with great geographical diversification as the foundation for growth
More informationFor personal use only
2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor
More informationCeQur establishes Wales subsidiary
FOR IMMEDIATE RELEASE CeQur establishes Wales subsidiary -- Arthurian Life Sciences investment helps bring to market world s first three-day simple insulin infusion device for type 2 diabetes -- LUCERNE,
More informationANNUAL GENERAL MEETING OF SHAREHOLDERS AFFIMED N.V.
ANNUAL GENERAL MEETING OF SHAREHOLDERS AFFIMED N.V. to be held on Tuesday, June 19, 2018 at 15:00 hrs. (CET) at Amsterdam Marriott Hotel, Stadhouderskade 12, 1054 ES Amsterdam, the Netherlands Agenda 1
More informationFor personal use only
ABN 82 010 975 612 Level 18 101 Collins Street, Melbourne Victoria 3000 Australia Telephone: + 61 7 3273 9133 Facsimile: + 61 7 3375 1168 http://www.tbgbio.com/public/ Investor Presentation Melbourne,
More informationWASHINGTON,D.C FORM8-K. CURRENTREPORT PursuanttoSection13or15(d)ofthe. Date of Report (Date of the earliest event reported): October29,2018
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)ofthe SecuritiesExchangeActof1934 Date of Report (Date of the earliest event reported):
More informationReinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &
More informationExperienced. Focused. Reliable.
Experienced. Focused. Reliable. Trusted advice during uncertain times. Argus Capital Partners LLC is an independent merchant banking firm focused on providing flexible and creative private equity solutions.
More informationAmaze AGM 2017 Non Executive Director Positions
Amaze AGM 2017 Non Executive Director Positions Core Competencies of Directors The Board requires that nominees demonstrate the following core competencies (noting that individual Directors will ordinarily
More informationLED HOLDINGS AND LIGHTING SCIENCE GROUP COMBINE FORCES. Transaction creates unique lighting solutions company with world class management team
Media Contact: Investor/Analyst Contact: Lewis Goldberg Zach Gibler KCSA Worldwide LED Holdings (212) 896-1216 (740) 644-2884 lgoldberg@kcsa.com zach.gibler@ledeffects.com LED HOLDINGS AND LIGHTING SCIENCE
More informationUBS Global Healthcare Services Conference February 14, 2006
UBS Global Healthcare Services Conference February 14, 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not
More informationYing Li. Proskauer.com. Partner. Hong Kong Beijing New York
Contact Ying Li Partner Hong Kong +852.3410.8088 Beijing +86.10.8572.1888 New York +1.212.969.3000 yli@proskauer.com Ying Li is a partner in the Corporate Department. Having been based in China and Hong
More informationWOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview
Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context
More informationCorporate Presentation
Suite 610-2010 11 th Avenue Regina, SK. S4P 0J3 Canada www.westernpotash.com Corporate Presentation August 2017 Western Potash Corp. Board of Directors Geoffrey Chang Chairman of the Board Appointed Chairman
More informationNEWSLETTER DECEMBER In This Issue. News. Highlights NOTE FROM THE CEO. Recent Additions to the Board. November's AGM Address
NEWSLETTER DECEMBER 2017 In This Issue NOTE FROM THE CEO Highlights November's AGM Address News Recent Additions to the Board A NOTE FROM THE CEO As people enter December and prepare for the holiday season,
More information2,500,000 Shares. Common Stock
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-201841 Prospectus Supplement No. 15 to Prospectus dated February 26, 2015 2,500,000 Shares Common Stock This Prospectus Supplement No. 15
More informationPANEL DISCUSSION & ROUNDTABLES
LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the
More informationSTEMEDICA EXPANDS GLOBALLY WITH INTERNATIONAL HEADQUARTERS IN SWITZERLAND
STEMEDICA EXPANDS GLOBALLY WITH INTERNATIONAL HEADQUARTERS IN SWITZERLAND For Immediate Release SAN DIEGO, California (April 9, 2009) Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell
More informationU. S. CHINA BUSINESS FORUM
U. S. CHINA BUSINESS FORUM TUESDAY, DECEMBER 15, 2009 MID-AMERICA CLUB 200 E. RANDOLPH, 80TH FLOOR AON CENTER, CHICAGO, IL 60601 Agenda 8:00 am Registration and Breakfast 8:45 am Welcome Remarks Mr. Gerald
More informationALBEDO RAISES $3 MILLION FOR CHINA EXPANSION
MEDIA RELEASE ALBEDO RAISES $3 MILLION FOR CHINA EXPANSION Shares placed to Mr Frankie Kiow, founder and CEO of leading China franchisor Wealth Union Albedo to manage Qingdao kidney hospital and aesthetic
More informationFS INVESTMENTS & KKR FORM STRATEGIC PARTNERSHIP. Combining FSIC & CCT platforms to create stockholder value
FS INVESTMENTS & KKR FORM STRATEGIC PARTNERSHIP Combining FSIC & CCT platforms to create stockholder value FS INVESTMENTS AND KKR TO ESTABLISH INDUSTRY-LEADING PARTNERSHIP FS Investments ( FS ) and KKR
More informationAccenture plc (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTHE GOLDMAN SACHS GROUP, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event
More informationCorporate presentation
Corporate presentation Let s chat! How can we support your business? What keeps you awake at night? Is your Leadership team ready for the Digital Transformation?? Your challenges in the Aviation industry
More informationManagement to Host Conference Call at 8:30 a.m. ET today
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),
More informationEndeavor Bank (in Organization) Begins Common Stock Offering The first bank to receive FDIC approval in San Diego County in 9 years
Contact: Dan Yates, CEO Endeavor Bank (In Organization) dyates@bankendeavor.com Mobile: (858) 230-5185 Office: (760) 795-1250 Endeavor Bank (in Organization) Begins Common Stock Offering The first bank
More informationHealthcare and Life Sciences
Healthcare and Life Sciences Introduction Uría Menéndez is an independent law firm that was founded in Madrid in 1946 by Professor Rodrigo Uría González. We currently have seventeen offices in Spain, Portugal,
More informationSPONSORED BY WORLD GOLD TRUST SERVICES, LLC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationGLP CHINA LEADERSHIP TRANSITION
For Immediate Release GLP CHINA LEADERSHIP TRANSITION Teresa Zhuge and Victor Mok promoted from within the China business to serve as Co-Presidents Dual leadership structure allows GLP to focus on strengthening
More informationTel: Mobile:
John Scutt Biography Tel: 02 8407 9372 Mobile: 0401 767 639 Email: john@lindfieldpartners.com.au John is Managing Director of The Lindfield Partners Pty Ltd trading as Essential Management Services (Lindfield
More informationDavid Chu. Matters. Proskauer.com. Partner. Hong Kong
Contact David Chu Partner Hong Kong +852.3410.8028 dchu@proskauer.com David Chu is a partner and heads our Litigation practice in Hong Kong and China. David's practice focuses on regulatory enforcement
More informationFINC915 Venture Lab Participating Firms: FALL 2010
FINC915 Venture Lab Participating Firms: FALL 2010 Please Note: The listed firms will consider candidates. Not all firms will eventually offer a position to students. LOCAL FIRMS: I2A Fund Number of slots:
More informationDean A. Connor. President & Chief Executive Officer, Sun Life Financial
Dean A. Connor President & Chief Executive Officer, Sun Life Financial Dean A. Connor was appointed President & Chief Executive Officer, Sun Life Financial on December 1, 2011, and is a member of the company
More informationCorporate Profile. Sep 2009
Corporate Profile Sep 2009 Executive Summary Oxley Capital Group is an innovative private investment firm specialising in private equity and real estate investments across the Asia-Pacific. Headquartered
More informationFor personal use only
ASX ANNOUNCEMENT 19 February 2019 BUSINESS OPERATIONS UPDATE Melbourne, Australia, Candy Club Holdings Limited (ASX: CLB) (the Company ) a leading premium confectionary business, is pleased to provide
More informationMore Gender Diversity Among General Counsels By Cynthia Dow and Lloyd M. Johnson Jr.
More Gender Diversity Among General Counsels By Cynthia Dow and Lloyd M. Johnson Jr. First, the good news: The number of women appointed to general counsel jobs in the Fortune 500 increased sharply again
More informationAcquisition of MST Medical Surgery Technologies Ltd:
Acquisition of MST Medical Surgery Technologies Ltd: Meaningfully Bolsters Senhance Platform Innovation to Further Advance Digital Laparoscopy September 24, 2018 2 FORWARD LOOKING STATEMENTS This presentation
More informationBiographical Details of Directors, Supervisors and Senior Management
Mr. Yang Jie Age 54, is the Chairman of the Board of Directors and Chief Executive Officer of the Company. Mr. Yang is a professor-level senior engineer. He graduated from the Beijing University of Posts
More informationFORWARD LOOKING STATEMENTS
1 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements and projections. The company makes no express or implied representation orwarrant as to the completeness of this information
More informationAdvaxis Investor and Analyst Day ADVAXIS. Tuesday, June 28, pm 4.30 pm ET (Event) 4.30 pm 5.30 pm ET (Reception)
Advaxis Investor and Analyst Day Tuesday, June 28, 2016 1.30 pm 4.30 pm ET (Event) 4.30 pm 5.30 pm ET (Reception) Offices of Reed Smith 599 Lexington Ave 22 nd Floor New York, NY 10022 ADVAXIS Advaxis
More information51JOB, INC. NOTICE OF ANNUAL GENERAL MEETING OF MEMBERS
51JOB, INC. NOTICE OF ANNUAL GENERAL MEETING OF MEMBERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of Members (the Meeting ) of 51job, Inc., a Cayman Islands exempted company (the Company ),
More informationLynn E. Turner Managing Director
Lynn E. Turner Managing Director 725 South Figueroa Street, Suite 2950 Los Angeles, CA 90017 main: 213.222.0870 fax : 888.222.6001 lturner@litinomics.com Lynn E. Turner is a Managing Director within the
More informationDaryn A. Grossman. Proskauer.com. Partner. New York
Contact Daryn A. Grossman Partner New York +1.212.969.3665 dgrossman@proskauer.com Daryn A. Grossman is co-chair of Proskauer s global Corporate Department. She serves as the head of the Life Sciences
More informationWILSON SONSINI GOODRICH & ROSATI
WILSON SONSINI GOODRICH & ROSATI IS PLEASED TO ANNOUNCE THAT THE FOLLOWING ATTORNEYS HAVE BECOME PARTNERS AT THE FIRM. Troy Foster Corporate & Securities, Palo Alto Jessica L. Margolis Litigation, New
More informationVenture Capital Search Highlights
Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more
More information1280 CENTRE STREET, SUITE 2, NEWTON CENTER, MA BAYBOSTON.COM
BAYBOSTON IS A PRIVATE EQUITY FIRM THAT INVESTS IN: Community Banks Financial Services Companies WE PROMOTE GROWTH. WE ARE A COMMUNITY BANKING VALUE ADVOCATE. ABOUT US BayBoston is a minority-owned private
More informationContact: Greg A. Smith Katja Gehrt Marshall & Ilsley Corporation Warburg Pincus
News Release Marshall & Ilsley Corporation 770 North Water Street Milwaukee, WI 53202 414 765-7700 Main 414 298-2921 Fax mibank.com For Release: Immediately Contact: Greg A. Smith Katja Gehrt Marshall
More informationPage 1 of 5 LEGAL_1:
Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018 Patient enrollment in the two TRILOGY Phase 3 studies is progressing as planned: 463 patients enrolled and 41 patients randomized at
More informationJOHN JACK R. TUPMAN, JR CURRICULUM VITAE
JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant
More informationInvestor Presentation. June 2006
Investor Presentation June 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, the impact of
More informationMillhouse, Inc. Plc GLOBAL CAPITAL. Commercial in Confidence. Copy Right 2012 Millhouse, Inc. PLC Version Thursday, 11 October 2012
Millhouse, Inc. Plc GLOBAL CAPITAL Millhouse, Inc. PLC Version 2.0 1 DISCLAIMER This presentation contains certain forward-looking statements within the meaning of the United States Private Securities
More informationMedtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year
www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for
More informationCrack the Code: Demystify the Success Factors for Career Development
Crack the Code: Demystify the Success Factors for Career Development March 1, 2014, Saturday Rutgers University 675 Hoes Lane West Piscataway, NJ 08854 Sino-American Pharmaceutical Professionals Association
More informationTHE GOLDMAN SACHS GROUP, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationWE PROMOTE GROWTH. WE ARE A FINANCIAL SERVICES VALUE ADVOCATE.
WE PROMOTE GROWTH. WE ARE A FINANCIAL SERVICES VALUE ADVOCATE. ABOUT US BayBoston is a minority-owned private equity firm that provides sophisticated strategic advice and capital to community banks and
More informationMichael Klump Chairman and Co-founder
TEAM EXPERIENCE At RCG Ventures, our highly skilled senior management team has over 165 years of combined retail real estate experience. As a fully-integrated real estate company, our team is comprised
More informationNVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations
February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and
More informationPlease join us as a committed sponsor to make the NC CEO Forum as spectacular, educational and enjoyable as ever. We can t do this without you!
INVITATION TO SPONSOR Currently in its eighth year, the North Carolina CEO Forum is an invitation-only leadership event that welcomes 400 senior business, government and non-profit leaders who are committed
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationNasdaq: RNVA. Diagnostics and supportive software solutions to healthcare providers.
Nasdaq: RNVA Diagnostics and supportive software solutions to healthcare providers. Forward looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova
More informationShell s Journey to Mobility
Shell s Journey to Mobility Speakers: Yorinde Knegtering Business Analyst, IT Produce Hydrocarbons Prabhat Mishra Product Owner, PI Center of Excellence Definitions & cautionary note Reserves: Our use
More informationForm FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.
Form 51-102FI SERNOVA CORP. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. The following discussion and analysis should be
More informationAll of the documents listed above are available on the Credit Suisse website.
Annual Report 2018 Zurich, Credit Suisse Group AG and Credit Suisse AG, today, published the 2018 annual reporting suite, comprising the Annual Report, the Corporate Responsibility Report and the publication
More informationB U R F O R D QUARTERLY
B U R F O R D QUARTERLY A review of litigation and arbitration finance AUTUMN 2016 ISSUE Recent rulings Judgment enforcement research update Year-end planning Arbitration finance CONTENTS The impact of
More informationShareholders are invited to the 2018 Annual Meeting which is scheduled for 27 September 2018.
7 September 2018 Dear Shareholder 2018 Annual Meeting of Shareholders Shareholders are invited to the 2018 Annual Meeting which is scheduled for 27 September 2018. The details of the Annual Meeting are
More informationBREAKTHROUGH CONVENTION SUMMARY JUNE SAN DIEGO CONVENTION.BIO.ORG #BIO2017
BREAKTHROUGH CONVENTION SUMMARY JUNE 19-22 SAN DIEGO CONVENTION.BIO.ORG #BIO BIO BY THE NUMBERS FEATURING SEVERAL THEMATIC EXHIBITS 16,123 ATTENDEES 74 48 COUNTRIES STATES 18,000 MORE THAN EXHIBITORS 41,400
More informationAssociate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive
Job Title Alliance Lead Analytics Specialist Associate Director Associate Director Diagnostics Partnering Associate Director Business Development Associate Director Application Architecture Associate Manager
More informationFortis to acquire strategic stake in Parkway Holdings, Singapore
PRESS RELEASE Fortis to acquire strategic stake in Parkway Holdings, Singapore Landmark cross border deal in Healthcare sector out of India Move will establish Fortis as Asia s largest hospital network
More information